About Lipum
Lipum is a company based in Umea (Sweden) founded in 2010 by Lennart Lundberg, Olle Hernell, and Susanne Lindquist. Lipum has raised $2.99 million across 7 funding rounds from investors including European Union, Almi and EIC Fund. Lipum offers products and services including SOL-116. Lipum operates in a competitive market with competitors including BeiGene, Moderna, Forge Biologics, Incyte and ALX Oncology, among others.
- Headquarter Umea, Sweden
- Founders Lennart Lundberg, Olle Hernell, Susanne Lindquist
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lipum Ab (Publ)
-
Annual Revenue
Not available
-
Net Profit
-$5.03 M (USD)-49.32as on Dec 31, 2024
-
EBITDA
-$4.58 M (USD)-55.18as on Dec 31, 2024
-
Total Equity Funding
$2.99 M (USD)
in 7 rounds
-
Latest Funding Round
$59.81 K (USD), Grant
Nov 30, 2020
-
Investors
European Union
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lipum
Lipum offers a comprehensive portfolio of products and services, including SOL-116.
Humanized antibody for treating rheumatoid arthritis and other inflammations.
People of Lipum
Unlock access to complete
Unlock access to complete
Funding Insights of Lipum
Lipum has successfully raised a total of $2.99M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $59.81 thousand completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lipum
Lipum has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Almi and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Investments are provided by Almi in seed to growth-stage startups.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by corporate-backed Almi Invest.
|
Locked | Locked | Locked |
Investor details for Lipum
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lipum
Investment portfolio details for Lipum
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lipum
Detailed financials for Lipum
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lipum Comparisons
Peer comparison for Lipum
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lipum
Lipum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Forge Biologics, Incyte and ALX Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Lipum
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lipum
Complete news archive for Lipum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lipum
Lipum was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Lipum is headquartered in Umea, Sweden.
Einar Ponten is the current CEO of Lipum.
Lipum is a funded company, having raised a total of $2.99M across 7 funding rounds to date.
Lipum has developed an antibody-based drug to treat juvenile idiopathic arthritis (JIA). The company has developed a monoclonal antibody (SOL-116) to target and block the function of protein denoted bile salt-stimulated lipase (BSSL) to treat chronic inflammatory diseases such as juvenile idiopathic arthritis.
Lipum's top competitors include Moderna, BeiGene and Forge Biologics.
Lipum offers SOL-116.
Lipum has 4 investors. Key investors include European Union, Almi, EIC Fund, and Almi Invest.